Aura Biosciences Inc AURA 深 滬
等待開盤 01-28 09:30:00 美东时间
5.66
+0.070
+1.25%
華盛通- 最 高5.68
- 今 開5.59
- 成交量 14.12万股
- 最 低 5.50
- 昨 收 5.59
- 總市值 3.59亿
- 52周最高 8.16
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.345
- 委 比 -56.98%
- 總股本 6350.33万
- 歷史最高 26.16
- 量 比 0.68
- 振 幅 3.22%
- 歷史最低 4.345
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Shares of High Roller Technologies Inc (NYSE:ROLR) rose sharply in pre-market t...
01-22 17:46
BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures...
2025-12-19 21:08
Aura Biosciences Q3 EPS $(0.40) Beats $(0.47) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.53 percent. This is a 4.76 percent increase over losses of $(0.42) per share from
2025-11-13 20:12
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
On September 3, 2025, Aura Biosciences, Inc. announced that its CEO, Elisabet de los Pinos, PhD, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 11:00 a.m. ET. The live webcast will be available on the "Investors & Media" page of the Company’s website, with a replay archived for 90 days. Aura Biosciences is a clinical-stage biotech company developing precision therapies for solid tumors to pr...
2025-09-03 11:00
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
2025-08-14 09:25
HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Aura Biosciences (NASDAQ:AURA) with a Buy and maintains $22 price target.
2025-08-14 01:36
Aura Biosciences Reports Q2 Results and $75M Financing
Aura Biosciences Inc ( ($AURA) ) just unveiled an announcement. On August 13, 2...
2025-08-13 19:27
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported Q2 2025 financial results, highlighting $75M equity financing and a $177.3M cash position to fund operations through 2027. The company advanced its bel-sar clinical programs in early choroidal melanoma and NMIBC, with ongoing Phase 3 and Phase 1b/2 trials. Recent developments include expanding ocular oncology indications and filing a patent for a new bel-sar formulation for bladder cancer. R&D expenses rose to $22.9M, wh...
2025-08-13 11:00
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
2025-05-29 09:53
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
2025-05-24 08:40
